Amoy Diagnostics Co (SZSE:300685) LT-Debt-to-Total-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Amoy Diagnostics Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.02.

Amoy Diagnostics Co's long-term debt to total assets ratio declined from Mar. 2023 (0.03) to Mar. 2024 (0.02). It may suggest that Amoy Diagnostics Co is progressively becoming less dependent on debt to grow their business.

Amoy Diagnostics Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Amoy Diagnostics Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co LT-Debt-to-Total-Asset Chart

Amoy Diagnostics Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.02

Amoy Diagnostics Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.02	0.02

Amoy Diagnostics Co LT-Debt-to-Total-Asset Calculation

Amoy Diagnostics Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	46.567	/	1934.882
	=	0.02

Amoy Diagnostics Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	45.738	/	1974.358
	=	0.02

Amoy Diagnostics Co (SZSE:300685) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Amoy Diagnostics Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amoy Diagnostics Co (SZSE:300685) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

39 Dingshan Road, Haicang District, Xiamen, CHN, 361027

Website

http://www.amoydx.com

Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.

Executives

Ruan Li	Directors, executives
Zheng Hui Bin	Directors, executives
Chen Ying	Directors, executives
Luo Jie Min	Executives
Zhu Guan Shan	Directors, executives
Yang Shou Qian	Securities Affairs Representative
Zhou Wen Gang	Executives
Zhou Xue Lin	Independent director
Hu Xu Bo	Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines